Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
In the STEP 1 trial, once weekly GLP-1 agonist at 2.4 mg with lifestyle intervention led to a mean body weight reduction of 14.9 percent at 68 weeks, compared with 2.4 percent with placebo 2
Marketed under the brand name Zepbound, it offers hope for adults struggling with obesity and is a game-changer in the landscape of weight-loss medications
It decreases your appetite, as well as your cravings for food
The program offers direct and consistent access to leading medical providers who oversee all aspects of the weight loss journey, including medical intake, diagnostic testing, treatment, and ongoing clinical support
Morphometric analysis showed that labeling for GSH was mainly associated with bacteroids and that the amount of label in the peribacteroid space remained constant throughout bacteroid differentiation (Table 2)
Valid only through 3/23/26
US$ 25.28
US$ 29.40
US$ 23.22
US$ 20.48
US$ 23.29
